Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

About this update from Opus Genetics, Inc.

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. Collaborative Community on Ophthalmic Innovation (CCOI) Asia-Pacific Academy of Ophthalmology Congress (APAO) Advanced Therapies Week Conference The Macula Society Annual Meeting About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit  www.opusgtx.com . Contacts: Investors Jenny Kobin Remy Bernarda IR Advisory Solutions [email protected] Media Kimberly Ha KKH Advisors 917-291-5744 [email protected] Source: Opus Genetics, Inc.

View stock analysis, news, and events for Opus Genetics, Inc.